During the corresponding time, Treace Medical Concepts Inc saw a revenue deteriorated by -4.24 % year on year, sequentially revenue fell by -3.86 %. While revenue at the Treace Medical Concepts Inc 's corporate clients
Treace Medical Concepts Inc's Comment on Sales, Marketing and Customers
The company markets and sells its surgical bunion correction systems primarily in the United States through a direct employee sales force and independent sales agencies. Its target customers include approximately 8,000 surgical podiatrists and 2,600 orthopedic surgeons specializing in foot and ankle care. The company provides training and education to physicians and operates a direct-to-patient outreach program to inform patients about its Lapiplasty System and other products. It supports surgeons with specialized teams and a Surgeon Advisory Board composed of surgical podiatrists and orthopedic foot and ankle surgeons. The market includes patients with bunions, a condition affecting nearly 25% of adults aged 18 to 65 and over 35% of those over 65 in the U.S. Approximately 4.5 million patients seek medical attention for bunions annually, with an estimated 1.1 million surgical candidates. About 450,000 surgical bunion procedures are performed annually in the U.S., with potential for growth if more candidates elect surgery.
Navigating Uncertainties: The Pomerantz Investigation and Treace Medical s Market Performance As the financial markets continue to fluctuate, investors are keenly observing developments involving Treace Medical Concepts, Inc. (NASDAQ: TMCI). This month, Pomerantz LLP, a well-respected law firm specializing in securities litigation, announced its investigation into potential claims on behalf of Treace Medical Concepts investors. The focus is on potential securities fraud or other unlawful business practices affecting the company s stock performance. This development arrives amidst Treace Medical s shares underperforming compared to the broader market, leading to heightened investor scrutiny and concern.Treac...
In the evolving field of podiatric surgery, Treace Medical Concepts, Inc. has emerged as a pioneer with its innovative solutions for treating bunions and midfoot deformities. The recent presentation of clinical study data at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona, signifies an important milestone for the company. By showcasing the promising outcomes of the Lapiplasty and Adductoplasty procedures, Treace is not only positioning itself as a leader in orthopedic surgery but also potentially redefining standard practices in bunion surgery. Overview of Clinical Studies At the ACFAS conference, Treace unveiled updated interim data from two key clinical studi...
Treace Medical Concepts Inc. has announced the expansion of its product portfolio into the high-volume osteotomy market with the introduction of its second minimally invasive surgical (MIS) osteotomy platform. The company aims to solidify its presence in the competitive bunion correction field through its new Percuplasty procedure, which utilizes a percutaneous 3D approach for bunion correction.By launching this advanced procedure, Treace positions itself to significantly increase its share of the overall bunion market. The innovative techniques involved in Percuplasty are expected to attract a broader base of surgeons, enhancing the company’s reach and customer demographic. The percutaneous nature of the ...
In the evolving landscape of medical technology, the orthopaedic sector is witnessing groundbreaking advancements. Among the frontrunners of this innovation is Treace Medical Concepts, Inc. which has recently introduced the Nanoplasty 3D, a minimally invasive bunion correction procedure poised to transform the field of bunion surgery.Bunions, a common foot ailment affecting millions of people worldwide, have long posed challenges in terms of effective and patient-friendly treatment options. Traditional surgical procedures are often invasive, requiring lengthy recovery times and carrying risks of complications. Treace s entry into the high volume osteotomy market with its cutting-edge Nanoplasty 3D could sign...
Treace Medical Concepts Inc’s Comment on Sales, Marketing and Customers
The company markets and sells its surgical bunion correction systems primarily in the United States through a direct employee sales force and independent sales agencies. Its target customers include approximately 8,000 surgical podiatrists and 2,600 orthopedic surgeons specializing in foot and ankle care. The company provides training and education to physicians and operates a direct-to-patient outreach program to inform patients about its Lapiplasty System and other products. It supports surgeons with specialized teams and a Surgeon Advisory Board composed of surgical podiatrists and orthopedic foot and ankle surgeons. The market includes patients with bunions, a condition affecting nearly 25% of adults aged 18 to 65 and over 35% of those over 65 in the U.S. Approximately 4.5 million patients seek medical attention for bunions annually, with an estimated 1.1 million surgical candidates. About 450,000 surgical bunion procedures are performed annually in the U.S., with potential for growth if more candidates elect surgery.
Sources:
Treace Medical Concepts Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Treace Medical Concepts Inc’s corporate clients.
For your research, we’ve provided 9 tables on Treace Medical Concepts Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
